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Abstract
Extracellular vesicles (EVs) are thought to be important in cell-cell communication and have
elicited extraordinary interest as potential biomarkers of disease. However, quantitative
methods to enable elucidation of mechanisms underlying release are few. Here, we
describe a cell-based assay for monitoring EV release using the EV-enriched tetraspanin
CD63 fused to the small, ATP-independent reporter enzyme, Nanoluciferase. Release of
CD63-containing EVs from stably expressing cell lines was monitored by comparing lucifer-
ase activity in culture media to that remaining in cells. HEK293, U2OS, U87 and SKMel28
cells released 0.3%-0.6% of total cellular CD63 in the form of EVs over 5 hrs, varying by cell
line. To identify cellular machinery important for secretion of CD63-containing EVs, we per-
formed a screen of biologically active chemicals in HEK293 cells. While a majority of com-
pounds did not significantly affect EV release, treating cells with the plecomacrolides
bafilomycin or concanamycin, known to inhibit the V-ATPase, dramatically increased EV
release. Interestingly, alkalization of the endosomal lumen using weak bases had no effect,
suggesting a pH-independent enhancement of EV release by V-ATPase inhibitors. The abil-
ity to quantify EVs in small samples will enable future detailed studies of release kinetics as
well as further chemical and genetic screening to define pathways involved in EV secretion.
Introduction
Extracellular vesicles (EVs) are released by cells and found in most biological fluids including
urine, plasma, cerebrospinal fluid, saliva etc. as well as in tissue culture conditioned media.
EVs are thought to mediate cell-cell communication [1] and may carry a variety of proteins,
lipids and RNA with potential to impact target cell physiology. It has been proposed that EVs
modulate tumor environments to allow for tumor seeding and growth and promote angiogen-
esis [2–8]. EVs have also been implicated in the prion-like spread of neuropathogenic protein
aggregates in several neurodegenerative diseases [9–15]. Certain viruses and bacteria such as
hepatitis A virus [16], herpesvirus 6 [17], HTLV-1 [18], HIV [19,20] and uropathogenic E. coli
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[21,22] may use the cellular pathways of EV biogenesis for extracellular release. Recent studies
in many laboratories have focused on exploring the utility of EVs isolated directly from biolog-
ical fluids as disease biomarkers [23,24]. Finally, EVs are also being developed as therapeutic
agents capable of delivering drugs to specific tissues or organs in the body [3,25,26].
EVs are produced in at least two distinct ways. Fusion of endosomal multivesicular bodies
(MVBs) with the plasma membrane releases intraluminal vesicles in the form of exosomes
whereas direct outward budding of the plasma membrane generates ectosomes, also referred
to as microvesicles. Based on the origin of EVs a number of proteins are well established as
markers. Among these are the tetraspanins characterized by four membrane spanning helices,
including most notably CD63 [27–31]. CD63 is predominantly localized to the intraluminal
vesicles (ILVs) of late endosomes and MVBs and is thus enriched on exosomes [31–33]. Cyto-
plasmic proteins including members of the endosomal sorting complex required for transport
(ESCRT) machinery, syntenin, and certain chaperones are also enriched in EVs [32,34]. In
addition, a variety of RNAs are present and thought to carry signals involved in cell-cell com-
munication [35–37]. Several packaged miRNAs have been shown to exert specific biological
effects supporting the notion that EV cargo is actively selected. Mechanistic understanding of
how cargo is selected and packaged into EVs and how EV release is regulated will be important
for future progress in this area.
EVs are small, ranging in size from ~50-140nm in diameter, making it difficult to monitor
them using light-based methods [38]. Most studies of EVs depend on efficiently collecting
them from cell culture media or biological fluids using high speed centrifugation or precipita-
tion-based methods [39]. As cultured cells produce small quantities of EVs, analytical studies
tend to require large volumes of conditioned media from cells cultured over one or more days
which may be contaminated with material associated with cell injury and death. Moreover,
typically used isolation procedures are inefficient, with extensive losses that preclude repro-
ducible and quantitative yield [40]. Thus, better methods are needed to quantify EVs in small
samples to facilitate chemical and genetic screens both to elucidate cell biological mechanisms
involved in EV biogenesis and to identify strategies to modulate EV production.
Here, we have developed a new cell-based assay system to quantitate EV release with high
sensitivity using stable cell lines expressing CD63 fused to a nanoluciferase reporter. Using this
assay system, we screen a set of known biologically active compounds to reveal pathway(s)
impacting EV release.
Materials and methods
Cells and Reagents
T-REx-293 cells were from Thermo Fisher (Cat# R71007). U2-OS, U87-MG and SKMel28
were purchased from the American Type Culture Collection (Manassas, VA). Cells were trans-
fected with the appropriate plasmids and stable transfectants were selected using 100 μg/ml
Zeocin (Thermo Cat #R25005) in DMEM (Gibco) with 10% fetal bovine serum (Atlanta Bio-
logicals). Nano-Glo Luciferase Assay System was purchased from Promega (Cat # N1110).
Antibodies used in this study are listed in S1 Table.
Plasmid construction
Plasmid pNL1.1[Nluc] carrying Nanoluciferase cDNA was a gift from Promega (Cat# N1001).
The Nluc gene was amplified using PCR with an upstream HA-tag along with appropriate
cloning sites for expression as either a soluble cytoplasmic protein (HANL) or as fusion at the
N-terminal end of CD63 gene (HANLCD63) in pcDNA4/TO plasmid (Thermo Fisher, Cat#
V102020) backbone.
Quantitative EV assay
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Nanoluciferase assays
TREx293 cells expressing HANL or HANLCD63 were grown in media without tetracycline
and induced with 1μg/ml tetracycline overnight (17h). We also compared this with cells con-
tinuously maintained in media containing a low concentration of tetracycline (0.2μg/ml) and
found no differences between the two paradigms. In this study, we maintained cells in media
containing 0.2μg/ml Tet to maintain cells in a constitutively ‘on’ state. Typically, 50–100,000
cells per well were plated in a 24-well plate as needed for the conditions to be tested. After 18-
24h for cell attachment, cells were washed twice with media to remove previously released
EVs. Fresh media containing appropriate drugs (as indicated in the figures) was added to cells
in 0.5ml media per well. Effects of the drugs were measured after indicated duration (typically
5 hours). At the end of the treatment, 250μl of conditioned media was removed into labeled
1.5ml tubes and centrifuged at 16000g for 5 minutes to remove large cell debris. Supernatants
(media & EV) were collected into fresh tubes. To the cells in the remaining 250μl of media in
the 24-well plate, 5μl of 10% Triton X100 was added (final 0.2%) to permeabilize cells and to
release all contents (total). We confirmed that Triton X100 does not alter Nluc activity in
HANL or HANLCD63 samples (see S2 Fig). 50μl of ‘media & EV’ samples and 1:10 diluted
‘total’ samples (5μl of sample+45ul of blank media) were transferred to 96-well plates (Costar
#3915). To each well containing sample, 25μl of Nano-Glo luciferase assay (Promega Cat#
N1110) reagent (prepared as per manufacturer’s instructions) was added. Luminescence was
measured immediately after reagent addition using a microplate reader (BioTek Synergy
hybrid H2). Background luminescence in media-only blanks was also measured within each
plate. Samples were measured in duplicates or triplicates and averages were plotted. To obtain
an unbiased quantitation of EVs in various samples, a ratio of luminescence in ‘media & EV’
to that in ‘total’ cell lystates is reported, termed ‘Fractional Release’.
Isolation of EVs by PEG precipitation
For precipitation of EVs from conditioned media, 1/3rd volume of 40% PEG 3350 prepared in
PBS was added to conditioned media for a final concentration of 10% PEG and incubated at
4C overnight. The mixture was centrifuged at 16,000g for 30 minutes at 4C. The pellet was
resuspended in PBS.
Immunofluorescence
For immunofluorescence experiments, 50,000 cells were plated in 0.5ml on untreated #1.5 cov-
erslips (12mm circle) in separate wells of a 24-well plate. Cells were fixed in 4% paraformalde-
hyde in PBS for 20 minutes at room temperature and moved to fresh wells containing 1ml of
PBS. Fixed cells were blocked and permeabilized in PBS containing 10% goat serum and 0.2%
saponin for 1h. Blocked coverslips were incubated in primary antibody dilutions made in the
blocking solution followed by 3 washes in PBS. Coverslips were incubated in secondary anti-
body dilutions made in the blocking solution followed by 3 washes in PBS. The coverslips were
given a final rinse in PBS, mounted on clean glass slides with gelvatol and allowed to set over-
night. Images were collected using a Nikon spinning disk confocal microscope equipped with
a CCD camera and Nikon Elements software.
Immunoblotting
For immunoblotting experiments, cells were seeded at a density of 200,000 cells per well of a
6-well plate with 3ml of growth medium. The conditioned media was collected and subjected
to PEG precipitation as described above. Cells were collected in 1ml of PBS into a 1.5ml tube
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and pelleted at 1000g for 3 minutes. The cell pellet was lysed in 100μl of hypotonic lysis buffer
containing 50mM Tris.HCl (pH 7.5), 0.1% sodium dodecyl sulfate (SDS), 1X protease inhibi-
tor cocktail (Roche) and 250 units/ml Benzonase (Sigma). After 5 minutes at room tempera-
ture, 35μl of 4X SDS-PAGE loading dye with 2-mercaptoethanol (for anti-HA blots) or
without 2-mercaptoethanol (for anti-CD63 blots) was added and the samples were boiled for 5
minutes. Samples were separated by SDS-PAGE and blotted onto nitrocellulose membrane.
Membrane was blocked with 10% non-fat dry milk in TBS with 0.1% Tween 20, followed by
incubations in primary and secondary antibody dilutions with 3 washes after each step. Blots
were developed using chemiluminescence and imaged on a BioRad Chemidoc. Bands were
quantified using the BioRad ImageLab software.
Results
Model development
To develop a high sensitivity assay for detecting CD63-containing EVs released by limited
numbers of cells over a short time into small volumes of culture media, we fused CD63 to the
smallest available reporter luciferase known as Nanoluciferase (Nluc). In addition to fusing
Nluc to CD63, we also developed a soluble Nluc reporter to monitor non-specific leakage of
cellular contents resulting from cell injury or death. Nluc is a 19kDa luciferase based on a natu-
rally occurring monomeric luciferase from the deep-sea shrimp, Oplophorus sp. [41]. Nluc uti-
lizes the coelenterazine analog furimazine as substrate to produce a bright glow-type
luminescence in an ATP-independent reaction. Nluc has been engineered for use in a variety
of applications requiring quantitative and sensitive measurements [41]. To enable antibody-
based monitoring of the fusion proteins we introduced a hemagglutinin (HA) tag at the N-ter-
minus of Nluc to generate HANL (Fig 1A). Since CD63 has a GYXXF-motif near its C-termi-
nus that binds clathrin adaptor proteins and is involved in sorting [42] and GFP fusions at the
N-terminus have been successful in previous studies [43,44], we fused HANL to the cyto-
plasmic N-terminus of CD63 to generate HANLCD63 (Fig 1A). HANL and HANLCD63 were
cloned under a tetracycline (Tet)-inducible promoter and transfected into cells for selection of
stable cell lines.
First, we examined the expression of these fusion proteins in Tet-inducible human embry-
onic kidney cells, TRex293 (HEK293), by immunoblotting (Fig 1B). Expression of HANL and
HANLCD63 was induced by adding Tet to TRex293 cell lines. We compared expression in
cells incubated overnight with a high concentration (1μg/ml) of Tet to that in cells grown in
the continuous presence of a low concentration (0.2μg/ml) of Tet over three passages (about
10 generations). Tet-induced expression of HANL or HANLCD63 did not affect the rate of
cell growth or cell number relative to uninduced controls (data not shown). Immunoblotting
cell lysates for CD63 revealed that HANLCD63 was expressed inducibly at a level comparable
to or less than that of endogenous CD63 (Fig 1B). Immunoblotting HANL samples for HA
showed that HANL was strongly induced in response to Tet (Fig 1B). Quantitation of bands in
Fig 1B showed that in Tet-induced samples expressing HANLCD63, an additional band at
~75kDa (band#1 in S1 Fig) corresponding to HANLCD63 was observed. Relative quantitation
of endogenous CD63 and HANLCD63 was not feasible since both endogenous CD63 and
HANLCD63 migrated as multiple bands (Fig 1B and S1 Fig). Similar results were obtained
using Tet-inducible U2OS cells (S1 Fig).
Next, we examined HANLCD63 and HANL localization by immunofluorescence and con-
focal microscopy (Fig 1C). We compared the distribution of HA-tag with that of the late endo-
some/lysosome protein, LAMP1. In cells expressing HANLCD63, HA-signal was distributed
similarly to that of LAMP1 on intracellular organelles. A small proportion of HANLCD63 was
Quantitative EV assay
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also observed on the plasma membrane as expected for endogenous and overexpressed CD63
[44]. In contrast, HA staining in HANL expressing cells was diffusely present throughout the
cytoplasm and distinct from LAMP1 confirming its cytoplasmic distribution as expected.
HANLCD63 expressed in U2OS cells also mostly colocalized with LAMP1 (S1 Fig).
EV release
To determine whether HANLCD63 will be useful as a marker of EV release, we next tested if
released HANLCD63 is detectable in conditioned media in association with EVs. To do this,
we added 10% polyethylene glycol (PEG) to conditioned cell media as described earlier [44]
and measured Nluc activity in PEG soluble and insoluble fractions (Fig 2A). Although PEG
precipitation is not selective for EVs, this method provides a simple and robust method for
quantitative collection of EV-associated CD63 from conditioned media [44]. In HANL sam-
ples nearly all of the Nluc activity was found in the PEG soluble fraction. In HANLCD63 sam-
ples most of the Nluc activity was found in the PEG insoluble fraction consistent with the
presence of HANLCD63 in EVs. We further confirmed this by immunoblotting PEG pellets
with CD63 antibody (Fig 2B). In PEG pellets from HANL cell media only a single band of
endogenous CD63 was detected with molecular weight of 50-60kDa (band# 2), whereas in
Fig 1. Development of a model system to quantify CD63-containing EVs. (A) Schematic diagram showing the locations of HA-tag, Nanoluciferase
and CD63. (B) Immunoblots of lysates of stably transfected TRex293 cells show inducible expression of HANLCD63 (top, anti-CD63 blot) and HANL
(bottom, anti-HA blot). Samples from cells grown in the absence of Tet (-), in the presence of high Tet (+++, 1μg/ml for 17h), or when continuously
cultured in low Tet (+, 0.2μg/ml over 3 passages). Lysates were blotted for actin to confirm equal loading. (C) Immunofluorescence of stably transfected
TRex293 cells cultured in media containing low concentrations of Tet to express HANLCD63 or HANL were immunostained for LAMP1 and HA
epitope tag. Bar = 10μm.
https://doi.org/10.1371/journal.pone.0220007.g001
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HANLCD63 derived samples additional bands at higher molecular weights (band# 1) were
observed consistent with additional recovery of HA tagged HANLCD63. The proportional sig-
nal in bands associated with HANLCD63 and endogenous CD63 is similar in cell lysates
(shown in Fig 1B) and EVs (shown in Fig 2B), suggesting that the tagged and endogenous pro-
tein are incorporated similarly into EVs. Together with the localization of HANLCD63 to
LAMP1-marked late endosomes and lysosomes, we conclude that the Nluc activity of
HANLCD63 can be used to monitor EV associated CD63.
To quantitatively track EV release from HANLCD63 expressing cells, we measured Nluc
activity in conditioned media as well as the total Nluc activity in HANLCD63 expressing
cells. This allowed us to report EV release in comparative terms as the ratio of extracellular
to total Nluc activity or ‘fractional release’. To do this, we collected conditioned media at the
time indicated and then replaced it with same volume of media containing 0.2% Triton X100
to extract HANLCD63 remaining in the cells. (See S2 Fig showing no effect of Triton X100
on Nluc activity of HANL and HANLCD63). In TRex293 (HEK293) cells, a small portion
(0.1–0.3%) of total cellular HANLCD63 was released in EVs during a 5 hr collection period
(Fig 3). For insight into how fractional release of EVs and cytoplasmic proteins varies among
different cell lines, we generated and characterized U2OS, SKMel28 and U87-MG cells stably
expressing HANLCD63. HANLCD63 was localized to LAMP1-positive endosomes as in
TRex293 cells (Fig 1C, S1 Fig and data not shown). Interestingly, different cell lines exhibited
different levels of EV release over a 5h period (Fig 3). While HEK293, U2OS and U87 cells
showed a fractional release of between 0.1%-0.4%, SKMel28 cells released about 0.6% of total
cellular HANLCD63. This result underscores the utility of this assay system for defining EV
production by different types of cells. We used stably transfected TRex293 cells for most
experiments in this study.
Fig 2. Characterization of EV release using HANLCD63. (A) Precipitation of EVs using polyethylene glycol (PEG). Samples are–complete
conditioned media (Total); supernatant after centrifugation at 14000g (14K sup); supernatant after PEG precipitation (PEG sup); pellet after PEG
precipitation (PEG pel). (B) PEG pellets immunoblotted for CD63. Band intensities were quantified using the BioRad ImageLab software.
https://doi.org/10.1371/journal.pone.0220007.g002
Quantitative EV assay
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Important clues to understanding EV biogenesis and how it can be modulated can come
from monitoring the kinetics of EV release. Given the inefficiencies of current exosome isola-
tion methods, EV release has, however, mostly been studied after single prolonged collection
times without time resolution or specific normalization to parent cells. Our model system is
well suited to monitoring the kinetics of EV release. To measure fractional release of EV asso-
ciated HANLCD63 or cytoplasmic HANL at different times after initiating collection, condi-
tioned media and cell extracts were collected and used to measure Nluc activity. The time
course of HANLCD63 release shows that low initial amounts of Nluc activity in the media
(roughly 0.1% of cellular HANLCD63) steadily increase over 6h, reaching a fractional release
of approximately 0.5%. This five-fold increase demonstrates both the sensitivity of this model
system for detecting changes in EV release and, importantly, that under these baseline condi-
tions EVs are being continuously released. In cells expressing HANL, the amount of Nluc pres-
ent in the media (roughly 0.2–0.3% of cellular HANL) remains unchanged over 6 hours (Fig
4A & 4B). Based on the fact that most extracellular HANL was not precipitated by adding PEG
(Fig 2A), we interpret its presence to reflect some form of cell or membrane damage, most
likely associated with media change and washing at the beginning of the experiment.
Screen for pathway perturbants
Existing methods of bulk EV isolation and analysis create a bottleneck for efforts to advance
understanding of EV biogenesis by screening compounds that modulate specific cellular
machinery. To begin to assess involvement of different cellular machineries in release of
CD63-containing EVs, we treated cells expressing HANL and HANLCD63 with various com-
pounds for 5 hrs. Conditioned media was collected at the end of treatment and Nluc activity
was measured (Fig 5). Note that this screening paradigm is most suitable for identifying
Fig 3. EV release in different cell lines. Comparison of EV release from TRex293 (HEK293), U2OS, U87 and
SKMel28 cells. Fractional release was compared using ordinary one-way ANOVA with Tukey’s multiple comparisons
test. �� = 0.005; ��� = 0.0003; ���� <0.0001.
https://doi.org/10.1371/journal.pone.0220007.g003
Quantitative EV assay
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compounds that stimulate EV release; longer EV collection times and/or cells that release high
levels of EVs is likely to be needed to uncover inhibitors of EV biogenesis.
The following five groups of compounds were tested:
1. Ion balance perturbants: oubain to inhibit sodium-potassium ATPase; amiloride to block
sodium channels; thapsigargin to inhibit the ER calcium channel, SERCA; MLSA1 to acti-
vate the endosomal calcium channel, TRPML1.
2. Lysosome perturbants: bafilomycin A1 to inhibit the V-ATPase proton pump; chloroquine
as a lysosomotropic alkalizing agent.
3. Cytoskeleton perturbants: nocodazole to depolymerize microtubules; latrunculin A to
block actin polymerization; jasplakinolide to induce actin polymerization.
4. Lipid perturbants: wortmannin to inhibit PI3 kinase; apilimod to inhibit PI3P-5-kinase;
amiodarone to accumulate LBPA in endosomes [45], methyl β-cyclodextrin to reduce cellu-
lar cholesterol; U18666A to inhibit lysosomal cholesterol export; 1-aminodecylidene bis-
phosphonic acid (ABPA) to inhibit acid sphingomyelinase; GW4869 to inhibit neutral
sphingomyelinase.
5. Other perturbants: ML240 to inhibit VCP/p97 AAA ATPase; 17-DMAG to inhibit Hsp90;
bortezomib to inhibit the proteasome; and Everolimus to inhibit mTORC1.
Fig 5 shows the effect of these compounds on extracellular Nluc released from cells express-
ing HANL or HANLCD63. None of the compounds tested had a significant effect on extracel-
lular Nluc activity in HANL samples (Fig 5), showing that as tested they did not compromise
cell integrity. While most of the compounds tested also did not change extracellular Nluc
released by cells expressing HANLCD63, a few significantly increased it indicating an
enhancement of EV biogenesis and/or release.
Most notable was the large increase in release of CD63-containing EVs triggered by treating
cells with bafilomycin, which we explore further below. Compounds that modulate Ca2+
Fig 4. Kinetics of EV release. EV release over 6h as measured with HANLCD63 (A). (B) Extracellular release of cytoplasmic HANL protein over 6h.
https://doi.org/10.1371/journal.pone.0220007.g004
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Fig 5. Screen for pathway perturbants. HANLCD63 (A) and HANL (B) expressing TRex293 cells were treated with
indicated compounds during a 5h EV collection. Nluc activity in media is shown as fold change over that released by
control cells (Ctrl). Compounds were used at the following concentrations: (i) Control—Ctrl (No drugs); (ii) Ion
balance perturbants—Oua (175nM Ouabain); Amil (100nM Amiloride); Thap (1μM Thapsigargin); MLSA1 (50μM
MLSA1); (iii) Lysosome perturbants—Baf (200nM Bafilomycin); CQ (50μM Chloroquine); (iv) Cytoskeleton
perturbants—Noco (1uμg/ml Nocodazole); LatA (2μM LatrunculinA); Jasp (2μM Jasplakinolide); (v) Lipid perturbants
—Wort (10μM Wortmannin); Apil (2μM Apilimod); Amio (10μM Amiodarone); MBCD (1mM MβCyclodextrin);
U18666A (7μM U18666A); ABPA (2μM 1-aminodecylidene bis-phosphonic acid); GW4869 (17.3μM GW4869); (vi)
Quantitative EV assay
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homeostasis also increased HANLCD63 release. TRPML1/MCOLN, a Ca2+ channel on the
endolysosomal membrane, has been implicated in control and release of endolysosomal Ca2+
and connected to exosome release [46]. Treating cells with MLSA1, an activator of TRPML1,
doubled HANLCD63-marked EV release, consistent with these earlier reports. Treating cells
with thapsigargin, which releases ER Ca2+ by inhibiting the sarco/endoplasmic reticulum Ca2+
ATPase (SERCA), also increased EV release, similar to previous observations [47]. These
results suggest that increases in Ca2+ from multiple sources can enhance EV release.
We also observed that compounds affecting the actin cytoskeleton, but not microtubules,
increased EV release. Both stabilizing actin filaments with jasplakinolide and inhibiting actin
polymerization with latrunculin A increased EV release in our screen, potentially by relieving
restrictions on exocytosis or enhancing blebbing of the plasma membrane. While we expected
that transport of endosomes/MVBs along microtubules might be important for exocytosis and
EV release, the lack of effect of nocodazole did not support such a role over the time course
measured. Further studies will be required to determine the exact role of the cytoskeleton in
EV biogenesis and/or release.
None of the lipid perturbants tested caused a significant change in CD63-EV release. Specif-
ically, depleting cellular cholesterol with methyl-β-cyclodextrin or increasing it with U18666A
had no effect on EV release. U18666A has previously been reported to have both stimulatory
[48] as well as inhibitory roles in EV biogenesis [49]. Another lipid perturbant, apilimod, has
been shown to cause a 50% increase in EV release over 20h of treatment [50]. Small stimula-
tory effects of this magnitude may not be obvious over the time course of our screen. Inhibi-
tory effects of drugs such as GW4869 previously shown to act over 16h of treatment [51] were
also not obvious in our screen. One possible explanation is that they would not be expected to
inhibit exocytosis of existing MVBs. It is also possible that overexpressing HANLCD63 may
diminish the sensitivity of EV biogenesis machinery to inhibitory drugs. Inhibitors of VCP/
p97, Hsp90 or the proteasome also did not have significant effects at the concentrations tested.
Finally, everolimus, a rapalog inhibitor of mTORC1 leading to hyperactivation of AKT signal-
ing reproducibly enhanced EV release (Fig 5).
As above, we saw the most striking increase in EV release following treatment with bafilo-
mycin, which inhibits the V-ATPase proton pump and thereby allows the lumenal pH of lyso-
somes to rise over seconds to minutes [52]. The observed increase in CD63-EV release is
consistent with previous reports of bafilomycin enhancing various types of EV release
[47,53,54], effects that have been attributed to the pH neutralizing effects of inhibiting the
V-ATPase. Curiously, however, we found that treating cells with chloroquine, which rapidly
neutralizes lumenal pH as a weak base, did not have any effect on HANLCD63 release. We set
out to explore the basis for this striking dichotomy.
First, we asked whether bafilomycin enhances EV release from naïve, untransfected,
HEK293 cells using traditional EV isolation and immunoblotting techniques. After treating
HEK293 cells with vehicle or bafilomycin for 5 hrs, we examined the accumulation of marker
proteins including CD63, CD9, flotillin and syntenin in PEG-concentrated EVs. Bafilomycin
treatment robustly increased release of all of these EV-associated proteins, consistent with a
Other perturbants—ML240 (5μM ML240); 17DMAG (2μM 17-DMAG); Vel (100nM Velcade); Ever (10μM
Everolimus). Data were compared in two ways–First, using two-way ANOVA with Tukey’s multiple comparisons test
to compare effects of each drug within each sample (HANL or HANLCD63). In HANLCD63 samples bafilomycin was
significantly more effective in increasing EV release than control (p = 0.01) and CQ (p = 0.0002). Second, we also
compared individual drug effects between HANL and HANLCD63 samples using multiple t-tests. This revealed that
bafilomycin and latrunculin A significantly increases EV release in HANLCD63 (p values were 1.77e-8 for Baf and
6.37e-4 for LatA).
https://doi.org/10.1371/journal.pone.0220007.g005
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broad based increase in EVs (Fig 6A). These results demonstrate that increased EV release fol-
lowing treatment with bafilomycin is a general phenomenon and not specific to cells overex-
pressing HANLCD63.
Next, to understand whether the difference in effects of the V-ATPase inhibitor and an
alkalizing agent on EV release might be due to differing effects on the total amount of cellular
CD63, we compared CD63 levels by immunoblotting cell lysates and PEG-concentrated EVs
after treatment with bafilomycin or chloroquine (Fig 6B and S3 Fig). Cell-associated CD63
increased comparably after 5 hours in either bafilomycin or chloroquine, suggesting that both
interfere with normal lysosomal activity. However, EVs isolated from these same cells showed
that treatment with bafilomycin increased EV-associated CD63 far more dramatically than did
treatment with chloroquine.
In order to test whether the enhanced release caused by bafilomycin is specific to EV secre-
tion, we examined its effect on the secretion of proteins that pass through the classical secre-
tory pathway and do not intersect EV biogenesis pathways. Specifically, we examined secreted
nanoluciferase (SecNL), a model protein for classical secretion developed by fusing IL6 secre-
tion signal to nanoluciferase (S4 Fig). Extracellular Nluc activity was measured in cells express-
ing HANLCD63 or SecNL during 2h after addition of bafilomycin. The extracellular:
intracellular ratio (fractional release) for SecNL increased to>600% within 2h under untreated
conditions and was greatly inhibited by bafilomycin. Extracellular release of HANLCD63 was
enhanced by bafilomycin as before. Bafilomycin has been previously observed to interfere
with classical secretion [55,56]. These results together with our results showing no effect of
Fig 6. Effects of lysosomal perturbants on EV release. (A) Analysis of EVs collected from naïve HEK293 cells treated with DMSO vehicle (-) or
200nM bafilomycin (+). PEG pellets from conditioned media collected over 5 hours were immunoblotted for CD63, CD9, flotillin 2 and syntenin as
markers of EVs. (B) HEK293 cells were treated with vehicle (Ctrl), 200nM bafilomycin (Baf) or 50μM chloroquine (CQ). Cell lysates (Cells) or PEG
pellets of conditioned media (EVs) were immunoblotted for CD63. (C) TRex293 cells expressing HANL or HANLCD63 were treated with indicated
compounds to inhibit various aspects of lysosome function. Nluc activity was measured in conditioned media and expressed as fold change over vehicle
treated (Ctrl) samples. Compounds used include–(i) V-ATPase inhibitors: Baf (200nM Bafilomycin); Con (100nM Concanamycin); (ii) weak bases: CQ
(50μM Chloroquine); AmmCl (2mM Ammonium Chloride); (iii) protease inhibitors: Leu (2.5μM Leupeptin); Pep (15μM Pepstatin); E64d (20μM
E64d); LPE mix (2.5μM Leupeptin, 15μM Pepstatin, 20μM E64d).
https://doi.org/10.1371/journal.pone.0220007.g006
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bafilomycin on release of cytoplasmic HANL demonstrate that the stimulatory effect of bafilo-
mycin is specific for EV protein release and not attributable to non-specific release of cellular
proteins resulting from dying cells.
Since MVBs either fuse with lysosomes for content degradation or with the plasma mem-
brane to release ILVs as exosomes, we posited that blocking lysosomal function with other
compounds would shed further light on trigger(s) responsible for enhanced EV release.
Using HANLCD63 expressing TRex293 cells we first tested the effect of another inhibitor of
V-ATPase function, concanamycin, as well as the weak base ammonium chloride [57,58].
Concanamycin stimulated EV release to levels comparable to that seen with bafilomycin,
while ammonium chloride again had no effect on EV release (Fig 6C). To test whether accu-
mulation of un-degraded proteins within lysosomes might promote HANLCD63 release,
we treated cells with lysosomal protease inhibitors (leupeptin, pepstatin, E64d) and mea-
sured extracellular Nluc. These inhibitors, either singly or in combination, also had no effect
on HANLCD63 release suggesting that accumulation of undegraded proteins in endolyso-
somes is not a strong trigger for EV release (Fig 6C). To understand whether the stimulatory
effect of V-ATPase inhibitors depends on changing organelle pH, we treated cells with bafi-
lomycin together with ammonium chloride or chloroquine. Stimulated release of
HANLCD63 by V-ATPase inhibition was unaffected by alkalizing agents (S5 Fig), suggest-
ing that inhibiting V-ATPase alone was necessary and sufficient to promote enhanced
release of HANLCD63.
Discussion
We report development of a facile cell-based assay system for sensitively quantifying release of
CD63-containing EVs in small volumes of conditioned culture media as a distinct phenome-
non from non-specific cell lysis. To do this, we fused a small ATP-independent luciferase to
the endolysosomal tetraspanin CD63 as a reporter for EVs. In addition, luciferase localized to
the cytoplasm was used as a reporter for non-specific release cytoplasmic due to damage and
injury to cells. This enables direct determination of EV marker release following different cell
treatments. Using these markers, we established that different cultured cell lines differ in EV
production. We also observed that EVs are constitutively and continuously released over a sev-
eral hour time period, again distinct from cytosolic leakage. This system enabled a first pass
broad-spectrum screen using compounds with known mechanistic targets, paving the way for
future delineation of mechanisms of EV biogenesis. An important finding from this screen
was the importance of V-ATPase activity in regulating EV release.
Our choice of luciferase was nanoluciferase (Nluc) because of its small size (19kDa), high
stability and bright glow-type luminescence that is stable for >30 min. Nluc luminescence is
ATP-independent and ~150 times brighter than firefly or Renilla luciferase [59]. Further, Nluc
has no disulfide binds and is therefore well suited for expression in the cytoplasm and on the
cytoplasmic extensions of transmembrane proteins such as CD63; this is distinct from another
small and bright luciferase derived from Gaussia which has many disulfide bonds and is there-
fore better suited for expression on lumenal extensions of transmembrane proteins [60]. Lucif-
erase-based tracking of exosomes and other EVs has been previously explored. Danzer et al.,
used a split Gaussia luciferase system to investigate the packaging and release specifically of
aggregated αSynuclein as cargo within exosomes in cultured cells [61]; the required aggrega-
tion step limited quantitative interpretation of EV release. Others have used membrane local-
ized versions of Gaussia luciferase to monitor EVs in vivo [62,63]. While this manuscript was
under preparation, another report of Nluc fused to the C-terminal end of CD63 confirms the
general utility of this tracer for tracking CD63-labelled membranes and EVs in vitro and in
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vivo [64]. However, C-terminal fusion of tracers to CD63 may perturb function of the GYXXF
sorting signal present at the C-terminus of CD63 [42,65,66].
As proof-of concept for using this system in pharmacological screens, we tested the effect of
treating Nluc marker expressing cells with compounds known to perturb ionic homeostasis,
lysosomal function, cytoskeletal structure and dynamics, lipid metabolism and proteostasis.
Our screening paradigm with a short EV collection time was better suited to identifying com-
pounds that enhance EV release. Results from this screen demonstrate that inhibitors of the
V-ATPase, bafilomycin and concanamycin, were profound stimulators of EV release demon-
strating the utility of this facile assay system in drug and genetic screens. However, with short
EV collection times we were unable to validate the effects of the previously described inhibitor
of EV biogenesis GW4869. This was potentially because the incubation period of 5h is shorter
than that (16h) reported in literature [51] and needed to observe an effect or because overex-
pression of HANLCD63 may enhance EV biogenesis and obscure the effect of inhibitory
drugs. Increases in the duration of drug treatment and EV collection may make the assay more
suitable for screening for inhibitors of EV biogenesis.
Our findings of bafilomycin-stimulated EV release are in agreement with earlier observa-
tions showing increased secretion of lysosomal enzymes upon treatment with bafilomycin
[53]. Bafilomycin-mediated stimulation of EV release was also observed in a recent paper [54],
wherein it was also shown that in HeLa cells, exosomes are retained on the plasma membrane
by the action of tetherin. These authors also demonstrated that treatment of cells with bafilo-
mycin interrupts cholesterol trafficking leading to cholesterol accumulation in endosomes and
exosomes. In our study, we found that compounds that increase or decrease cholesterol did
not alter EV release suggesting that accumulation of endosomal cholesterol was not likely to be
the trigger for increased EV release. In K562 cells, small increases were observed in exosome
release after treatment with either bafilomycin or chloroquine [47]. Importantly, in our
HEK293-based system, unlike bafilomycin treatment, EV release could not be increased either
by alkalizing of endosomal lumen or by inhibiting lysosomal proteases. This suggests that nei-
ther the lumenal pH of endosomes nor the lysosomal degradative capacity was responsible for
increased exocytosis. An in vivo study in C. elegans revealed that the V-ATPase mediated apical
secretion of exosomes containing hedgehog-related proteins [67].
How might V-ATPase inhibition by bafilomycin or concanamycin stimulate EV release?
EV biogenesis can be influenced by perturbations at various steps including generation of
intralumenal vesicles, endosomal trafficking of CD63, motility of endosomes as well as exocy-
tosis. It is possible that the V-ATPase complex itself might somehow be responsible for
increased exocytosis. Bafilomycin and concanamycin bind to V0-ATPase complex presumably
at the interface of the a- and c-subunits that sits in the lipid bilayer [68–73]. Binding of these
inhibitors is thought to interfere with the helical swiveling required for proton translocation
[74]. It is thought that association and dissociation of V1-ATPase complex with the V0 com-
plex is a key regulatory step for many cellular pathways [74] including exocytosis of synaptic
vesicles [75]. The V0-V1 ATPase complex has been shown to recruit key signaling machinery
such as the mTOR kinase that sense endolysosomal function and generate an appropriate
response to regulate protein synthesis and cholesterol transport (reviewed in [76,77]). Kozik
et al, found an important role for V-ATPase in clathrin-coated vesicle formation [78]. Johnson
et al, found that lower V-ATPase activity coincided with localization of endolysosomes to the
cell periphery [52], which could increase the probability of exocytosis and EV release. Merku-
lova et al, mapped several protein-protein interactions with the B1 subunit of the cytoplasmic
V1 ATPase complex and found that some (eg, rabconnectin 3) were involved in Rab3-me-
diated exocytosis [79]. V-ATPase was found to be required for Rab27B-dependent invasive
growth and metastasis in breast cancer [80] suggesting that V-ATPase and the Rab GTPase
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implicated in exosome biogenesis were functionally connected. Clear understanding of
whether bafilomycin increases or decreases the abundance of the V0-V1 holoenzyme and its
role in the association of exocytic machinery will illuminate its mode of action in exocytosis.
Because MVBs can target lumenal cargo proteins for either degradation by fusion with lyso-
somes or extracellular release by fusion with plasma membrane, it is reasonable to hypothesize
that the V-ATPase may contribute to general proteostasis by its ability to sense endosomal/
lysosomal function in order to shunt undegraded potentially damaging proteins out of the cell
by exocytosis. In support of this idea, it has been observed that in C. elegans neurons stress
resulted in the expulsion of a bolus of protein aggregates by exocytosis [81]. The autophagy
protein, Atg5, was shown to dissociate the V1E subunit from the V0-V1 ATPase complex to
promote exosome production [82]. These observations suggest that reduced V-ATPase func-
tion due to accumulation of protein aggregates in endosomes/lysosomes may lead to extracel-
lular release of potentially pathogenic protein aggregates which in turn could spread disease
pathology in the brain. Further work is needed to delineate the underlying mechanisms by
which V-ATPase facilitates EV release.
Conclusions
In this study, we have developed a novel model system for quantitatively assaying small
amounts of CD63-containing EVs. We have demonstrated the utility of such a model system
in screening for compounds affecting pathways important in cargo-selection, packaging and
exocytosis events leading to EV release. Using this novel model system, we have identified the
V-ATPase as an important regulator of EV secretion. Given the bright luminescence from
Nluc, we predict that the construct presented in this paper may also be successfully used in
vivo in surface as well as deep tissues as previously demonstrated [83].
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